Meet-the-Professor Session:
109. Second Generation B-Lactamase Inhibitor Combinations: Promise and Peril
Friday, October 6, 2017: 7:00 AM-8:15 AM
Room: 15AB

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • discuss the clincial impact of emergence of resistance against newer B-lactam-B-lactamase inhibitor combination
  • discuss the clinical implications of therapy and resistance against newer B-lactam-B-lactamase inhibitor combinations
  • review the epidemiology and mechanisms of resistance aginst newer B-lactam-B-lactamase inhibitor combinations

Target Audience: Academicians, Clinicians, Epidemiologists, Fellows, Healthcare workers, Hospital epidemiologists, Infection preventionists, Infectious diseases pediatricians, Infectious diseases physicians, Investigators, Lab personnel, Medical students and residents, Members-in-training, Microbiologists, Nurses, Pharmacists, Scientists

Tracks: Trainee, Pediatric ID, Investigative ID, Epidemiology and Infection Control, Adult ID


Moderators:  Cesar Arias, MD, PhD, FIDSA, University of Texas McGovern Medical School , Robert A. Bonomo, MD, Case Western Reserve University and David R. Andes, M.D., FIDSA, University of Wisconsin School of Medicine and Public Health

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE

ACPE Number: 0221-9999-17-262-L01-P

Disclosures:

C. Arias, The Medecins Company: Grant Investigator , Research grant
Allergan: Grant Investigator , Research grant
Merck: Grant Investigator , Grant recipient

R. A. Bonomo, Entasis: Grant Investigator , Research grant
Allecra: Grant Investigator , Research grant
Wockhardt: Grant Investigator , Research grant
Merck: Grant Investigator , Research grant
Roche: Grant Investigator , Research grant
GSK: Grant Investigator , Research grant
Allergan: Grant Investigator , Research grant
Shionogi: Grant Investigator , Research grant

D. R. Andes, Medicines: Consultant , Consulting fee
Zavante: Consultant and Grant Investigator , Consulting fee and Grant recipient
Paratek: Research Contractor , Research grant
Actelion: Grant Investigator , Grant recipient
Amplyx: Grant Investigator , Grant recipient
Geom: Grant Investigator , Grant recipient
Meiji: Grant Investigator , Grant recipient
Cidaria: Grant Investigator , Grant recipient
Theravance: Consultant and Grant Investigator , Consulting fee and Grant recipient
Astellas: Grant Investigator , Grant recipient

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.